Dicerna on Novo's billion-dollar acquisition: Alleged wrongdoing has no hold in reality

US-based biotech firm Dicerna is distancing itself from the suits filed by its shareholders, following the announcement of Novo Nordisk's planned acquisition of the firm.
Photo: Novo Nordisk / PR
Photo: Novo Nordisk / PR
by BENJAMIN WERNER CHRISTENSEN, translated by daniel pedersen

Claims of alleged wrongdoing have no hold in reality, says Dicerna in a filing sent to the US Securities and Exchange Commission.
This stance has been taken by Dicerna after some shareholders have filed suits against the firm, alleging violations of the US Securities Exchange Act.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading